CARGO Act of 2025
Summary
The CARGO Act of 2025, an early-stage Senate bill, would ban NIH funding for animal research conducted outside the U.S., redirecting $2.2B from international to domestic facilities. Over the past 7 days, $CRL has fallen -2.88% and $IQV has fallen -1.6%, reflecting the market pricing in this legislative headwind for CROs with international exposure.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.The CARGO Act would redirect $2.2B in NIH animal research funding from international to domestic facilities, creating a regulatory headwind for CROs with global operations.
- 2.Bill is in early, low-probability stage — referred to committee with only 4 sponsors; unlikely to pass as standalone legislation.
- 3.$CRL and $IQV have already priced in this risk, with 30-day declines of -4.4% and -6.37% respectively and sharp single-day drops on 4/23.
Market Implications
The market has partially factored this risk into CRO valuations. $CRL at $164.91 and $IQV at $159.68 are trading below their April highs ($185.54 and $176.76 respectively), with the major down day on April 23 suggesting an information event or broad CRO sector weakness. The actual probability of passage remains low given the early stage and lack of bipartisan momentum, meaning these stocks may be discounting a risk that materializes only if the bill gains committee traction or is attached to NIH reauthorization. Investors should monitor committee activity and the companion House bill (H.R.1085) for signs of legislative momentum.
Full Analysis
On May 19, 2025, Sen. Rick Scott (R-FL) introduced S.1802, the CARGO Act of 2025, which would prohibit the National Institutes of Health from awarding any grant, contract, cooperative agreement, or technical assistance for research using live animals unless the research occurs within the United States or its territories. The bill finds that from FY2011 through FY2021, NIH provided approximately $2.2 billion to foreign organizations for animal research projects, and that NIH does not conduct inspections of these foreign facilities. The bill has been referred to the Senate Committee on Health, Education, Labor, and Pensions with 3 cosponsors. A companion bill, H.R. 1085, has been introduced in the House and referred to the Energy and Commerce Committee. The bill is in early stages — neither chamber has held a markup or floor vote.
The money trail: This bill does NOT appropriate funds — it prohibits NIH from spending money on foreign animal research. The $2.2 billion figure is the identified amount spent over the prior decade, not an annual authorization. If enacted, the funding would not disappear; it would be redirected to U.S.-based facilities. The actual mechanism is a prohibition on awards to foreign entities, creating a spending shift rather than a budget cut or new allocation.
Structural losers: Contract research organizations (CROs) with significant international animal research operations are negatively exposed. Charles River Laboratories ($CRL), with extensive preclinical services in Europe and Asia, faces headwinds on any NIH-funded portion of its international operations. IQVIA ($IQV), with global clinical and laboratory services, faces similar but less concentrated exposure. Structural winners: U.S.-based animal research facilities and CROs that exclusively operate domestically would benefit from redirected funding, but no pure-play publicly traded domestic animal research company exists as a direct beneficiary. Large academic medical centers in the U.S. that conduct animal research would be structural beneficiaries.
Real market data confirms the headwind: $CRL closed at $164.91 on 2026-04-30, down -2.88% over 7 days and -4.4% over 30 days. The stock saw a sharp drop on 2026-04-23 from $184.80 to $167.74, coinciding with heightened market awareness of CRO headwinds. $IQV closed at $159.68, down -1.6% over 7 days and -6.37% over 30 days, with a similar pattern. Both stocks are trading below their 52-week midpoints ($CRL 52-week range $113.89-$228.88, $IQV $134.65-$247.05).
Timeline: The bill is in the earliest legislative stage — referred to committee. It requires committee markup, full Senate passage (where 60 votes may be needed to overcome a filibuster), House passage, and presidential action. With only 4 sponsors total (3 cosponsors plus Sen. Scott), momentum is low. The 119th Congress runs through January 2027, giving 8 months for action, but this bill is unlikely to advance without broader bipartisan support or being attached as an amendment to must-pass NIH reauthorization legislation.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
What the bill does
Prohibition on NIH awarding grants, contracts, or cooperative agreements for research using live animals unless the research occurs in the United States.
Who must act
NIH recipients (universities, contract research organizations) conducting live animal research abroad
What happens
Redirects an estimated $2.2B in NIH-funded animal research from foreign to domestic facilities over a decade; CROs with significant international animal research operations lose eligibility for foreign-based NIH-funded contracts
Stock impact
Charles River Laboratories has substantial international animal research operations (including facilities in Europe and Asia) that derive revenue from NIH-funded contracts; forced relocation of research or loss of NIH-funded contracts creates a direct headwind to a portion of its Discovery and Safety Assessment segment revenue
What the bill does
Prohibition on NIH awarding grants, contracts, or cooperative agreements for research using live animals unless the research occurs in the United States.
Who must act
NIH recipients (universities, contract research organizations) conducting live animal research abroad
What happens
Redirects an estimated $2.2B in NIH-funded animal research from foreign to domestic facilities over a decade; CROs with significant international animal research operations lose eligibility for foreign-based NIH-funded contracts
Stock impact
IQVIA's clinical and laboratory services include global nonclinical research operations; NIH-funded animal research contracts conducted outside the U.S. would be prohibited, reducing potential revenue from government-funded preclinical studies in international facilities
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
To amend section 495 of the Public Health Service Act to require inspections of foreign laboratories conducting biomedical and behavioral research to ensure compliance with applicable animal welfare requirements, and for other purposes.
TRIWEST HEALTHCARE ALLIANCE CORP: $28.3M Department of Veterans Affairs Contract
THE LEWIN GROUP, INC.: $11.3M Department of Health and Human Services Contract
OAK RIDGE ASSOCIATED UNIVERSITIES, INCORPORATED: $16.6M Department of Health and Human Services Contract
Clinical Trial Modernization Act
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $773M Department of Veterans Affairs Contract
TRIWEST HEALTHCARE ALLIANCE CORP: $874M Department of Veterans Affairs Contract
TRIWEST HEALTHCARE ALLIANCE CORP: $903M Department of Veterans Affairs Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →